


PHARMACEUTICAL 2022



DICE Therapeutics Inc. Rank 72 of 475





PHARMACEUTICAL 2022



DICE Therapeutics Inc. Rank 72 of 475



The relative strengths and weaknesses of DICE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DICE Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 216% points. The greatest weakness of DICE Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 86%, being 362% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	323,911
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,881
Liabilities, Non-Current	1,916
Other Assets	198
Other Compr. Net Income	-58
Other Expenses	1,492
Other Liabilities	8.0
Other Net Income	136
Property and Equipment	1,645
Research and Development	36,506
Revenues	1,125
Selling, General and Administrative Expense	12,222

Output Variable	Value in 1000 USD
Assets	325,754
Liabilities	12,805
Expenses	50,220
Stockholders Equity	312,949
Net Income	-48,959
Comprehensive Net Income	-48,988
Economic Capital Ratio	86%